Last reviewed · How we verify
YG1699
At a glance
| Generic name | YG1699 |
|---|---|
| Sponsor | Youngene Therapeutics Inc., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- PK and PD of YG1699 in CKD Patients With Diabetes (PHASE1)
- To Evaluate the Safety, Tolerability, and Pharmacokinetics of YG1699（Antidiabetic） in Healthy Chinese Sbjects (PHASE1)
- A Comparison of Postprandial Glucose After a MMTT, and the Metabolic Effects of Insulin Withdrawal in a Crossover Study in Subjects With Type 1 Diabetes (PHASE2)
- A Randomized, Double-blind, Placebo-controlled, Sequential Single and Multiple Ascending Doses of YG1699 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- YG1699 CI brief — competitive landscape report
- YG1699 updates RSS · CI watch RSS
- Youngene Therapeutics Inc., Ltd. portfolio CI